COMP <GO>
LMAT vs NVCR // DIVIDEND YIELD & FCF PAYOUT SAFETY
LeMaitre Vascular Inc. (NASDAQ) VS. NovoCure Limited (NASDAQ) • 15-METRIC TALLY: LMAT 10
— NVCR 1
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LMAT
LAST: $81.26 (+0.40%) • MKT CAP: $1.85B
dividend-safety
0.93%
LAST: $13.21 (+0.46%) • MKT CAP: $1.54B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LMAT VS. NVCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LMAT | NVCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.50% | 74.50% | -3.00 | NVCR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.70% | -27.50% | +42.20 | LMAT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 28.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.17% | -4.96% | +9.13 | LMAT | /fcf-yield <GO> |
| Operating Margin | 27.20% | -23.50% | +50.70 | LMAT | /operating-margins <GO> |
| Net Profit Margin | 23.10% | -20.80% | +43.90 | LMAT | /net-margins <GO> |
| Revenue Growth (YoY) | 13.50% | 8.30% | +5.20 | LMAT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.93% | 0.00% | +0.93 | LMAT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.30 | 0.54 | +6.76 | LMAT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | LMAT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.3 | 34.3 | +12.00 | LMAT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.4x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.85B | $1.54B | $313.6M | LMAT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LMAT REV | NVCR REV | LMAT GROSS % | NVCR GROSS % | LMAT FCF | NVCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $249.6M | $655.4M | 71.5% | 74.5% | $81.3M | -$75.7M |
| FY 2024 | $219.9M | $605.2M | 68.6% | 77.3% | $44.1M | -$69.2M |
| FY 2023 | $193.5M | $509.3M | — | — | $36.8M | -$73.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LMAT // BETA —
NVCR // BETA —